Valuation, from the filing
| Public float | $2.50B | Market value of stock held by non-affiliates, as stated on the cover page for 2025-06-30 |
|---|---|---|
| Float per share | $9.60 | Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself. |
| Float / net income | 13.4× | A lower bound on the multiple, because affiliate holdings are excluded. |
| Float / revenue | 0.4× | A lower bound on the multiple, because affiliate holdings are excluded. |
| Float / equity | 3.3× | A lower bound on the multiple, because affiliate holdings are excluded. |
Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.
Valuation over time
13.4× earnings today, against a median of 6.1× across 5 years on record. Above its own history.
| Float measured | Public float | Float / net income | |
|---|---|---|---|
| 2025-06-30 | $2.50B | 13.4× | |
| 2024-06-30 | $5.30B | 6.1× | |
| 2023-06-30 | $5.30B | 5.2× | |
| 2022-06-30 | $8.60B | 9.4× | |
| 2021-06-30 | $7.67B | 5.7× |
Each float is paired with the fiscal year the filing that stated it covers. Only years where the company reported positive net income appear, because a multiple against a loss is not a multiple.
How this compares in its industry
Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.
| Measure | Reported | Percentile | |
|---|---|---|---|
| Long-term debt / equity | 11.47x | 97th | |
| SBC / revenue | 1.2% | 6th | |
| Effective tax rate | 56.0% | 94th | |
| Net margin | 3.0% | 79th | |
| FCF margin | 8.7% | 78th | |
| Current ratio | 1.82x | 26th | |
| Gross margin | 53.3% | 30th | |
| Revenue YoY growth | -2.9% | 39th | |
| CapEx / revenue | 2.6% | 56th |
Organon & Co. (OGN) reported revenue of $1.57B and net income of $164.00M for the fiscal year ended 2026-09-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Organon & Co.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.
Income
| Metric | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.57B | $1.56B | $1.46B | $1.51B | $1.60B | $1.59B | $1.51B | $1.59B | $1.58B | $1.61B |
| Cost of revenue | $705.00M | $711.00M | $677.00M | $766.00M | $745.00M | $720.00M | $672.00M | $696.00M | $659.00M | $668.00M |
| Gross profit | $869.00M | $847.00M | $783.00M | $741.00M | $857.00M | $874.00M | $841.00M | $896.00M | $923.00M | $939.00M |
| Operating income | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Net income | $164.00M | $108.00M | $146.00M | -$205.00M | $160.00M | $145.00M | $87.00M | $109.00M | $359.00M | $195.00M |
| Research & development | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Weighted-average diluted shares | shares 272.38M | shares 270.45M | shares 262.90M | Unavailable | shares 260.65M | shares 260.16M | shares 261.00M | Unavailable | shares 259.76M | shares 258.60M |
| Pretax income | $255.00M | $183.00M | $213.00M | -$148.00M | $243.00M | $229.00M | $101.00M | $129.00M | $207.00M | $235.00M |
| Income tax expense | $91.00M | $75.00M | $67.00M | $57.00M | $83.00M | $84.00M | $14.00M | $20.00M | -$152.00M | $40.00M |
| Diluted EPS | $0.60 | $0.40 | $0.55 | Unavailable | $0.61 | $0.56 | $0.33 | Unavailable | $1.38 | $0.75 |
| Selling, general & administrative | $421.00M | $434.00M | $424.00M | $433.00M | $415.00M | $453.00M | $420.00M | $470.00M | $422.00M | $437.00M |
| General & administrative | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Selling & marketing | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Balance
| Metric | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $1.46B | $1.13B | $1.12B | $574.00M | $672.00M | $599.00M | $547.00M | $675.00M | $763.00M | $704.00M |
| Total assets | $13.40B | $13.18B | $13.00B | $12.87B | $13.55B | $13.50B | $13.16B | $13.10B | $12.75B | $12.15B |
| Current assets | $5.37B | $5.11B | $4.93B | $4.35B | $4.70B | $4.62B | $4.37B | $4.35B | $4.76B | $4.51B |
| Total liabilities | $12.21B | $12.17B | $12.09B | $12.12B | $12.65B | $12.77B | $12.61B | $12.63B | $12.26B | $12.01B |
| Current liabilities | $2.65B | $2.62B | $2.50B | $2.39B | $2.68B | $2.80B | $2.62B | $2.72B | $2.79B | $2.76B |
| Total equity incl. NCI | $1.19B | $1.01B | $903.00M | $752.00M | $906.00M | $733.00M | $542.00M | $472.00M | $493.00M | $144.00M |
| Temporary (mezzanine) equity | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Inventory | $1.36B | $1.35B | $1.37B | $1.41B | $1.49B | $1.45B | $1.36B | $1.32B | $1.38B | $1.29B |
| Accounts receivable | $1.48B | $1.49B | $1.38B | $1.33B | $1.48B | $1.48B | $1.46B | $1.36B | $1.68B | $1.62B |
| Goodwill | $4.15B | $4.15B | $4.15B | $4.15B | $4.68B | $4.68B | $4.68B | $4.68B | $4.60B | $4.60B |
| Long-term debt | $8.48B | $8.48B | $8.55B | $8.63B | $8.78B | $8.78B | $8.94B | $8.86B | $8.74B | $8.65B |
| Accounts payable | $982.00M | $1.05B | $983.00M | $952.00M | $1.07B | $1.07B | $1.01B | $1.15B | $1.09B | $1.24B |
Cash flow
| Metric | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $370.00M | $107.00M | $225.00M | $141.00M | $264.00M | $220.00M | $75.00M | $390.00M | $141.00M | $332.00M |
| Capital expenditures | $44.00M | $42.00M | $37.00M | $45.00M | $46.00M | $39.00M | $32.00M | $55.00M | $42.00M | $32.00M |
| Investing cash flow | -$44.00M | -$76.00M | $386.00M | -$65.00M | -$115.00M | -$38.00M | -$172.00M | -$296.00M | -$75.00M | -$46.00M |
| Financing cash flow | -$5.00M | -$12.00M | -$38.00M | -$187.00M | -$76.00M | -$223.00M | -$75.00M | -$82.00M | -$78.00M | -$134.00M |
| Net change in cash | $323.00M | $16.00M | $542.00M | -$98.00M | $73.00M | $52.00M | -$128.00M | -$88.00M | $59.00M | $129.00M |
| Stock-based compensation | $21.00M | $25.00M | $19.00M | $7.00M | $24.00M | $22.00M | $24.00M | $26.00M | $25.00M | $28.00M |
| Common dividends paid | $5.00M | $6.00M | $5.00M | $4.00M | $3.00M | $10.00M | $71.00M | $74.00M | $74.00M | $79.00M |
| Common share repurchases | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Depreciation & amortization | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Derived
| Metric | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|
| Free cash flow | $326.00M | $65.00M | $188.00M | $96.00M | $218.00M | $181.00M | $43.00M | $335.00M | $99.00M | $300.00M |
| Gross margin | 55.2% | 54.4% | 53.6% | 49.2% | 53.5% | 54.8% | 55.6% | 56.3% | 58.3% | 58.4% |
| Operating margin | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| FCF margin | 20.7% | 4.2% | 12.9% | 6.4% | 13.6% | 11.4% | 2.8% | 21.0% | 6.3% | 18.7% |
| SBC / revenue | 1.3% | 1.6% | 1.3% | 0.5% | 1.5% | 1.4% | 1.6% | 1.6% | 1.6% | 1.7% |
| Current ratio | 2.02x | 1.95x | 1.97x | 1.82x | 1.75x | 1.65x | 1.67x | 1.60x | 1.70x | 1.64x |
| Revenue YoY growth | -1.7% | -2.3% | -3.5% | -5.3% | 1.3% | -0.8% | -6.7% | -0.4% | 4.1% | -0.1% |
| Net margin | 10.4% | 6.9% | 10.0% | -13.6% | 10.0% | 9.1% | 5.8% | 6.8% | 22.7% | 12.1% |
| R&D / revenue | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| CapEx / revenue | 2.8% | 2.7% | 2.5% | 3.0% | 2.9% | 2.4% | 2.1% | 3.5% | 2.7% | 2.0% |
| Long-term debt / equity | 7.11x | Unavailable | Unavailable | 11.47x | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Effective tax rate | 35.7% | 41.0% | 31.5% | Unavailable | 34.2% | 36.7% | 13.9% | 15.5% | -73.4% | 17.0% |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open OGN in the interactive workspace to inspect any figure back to its filing.
Source filings
Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.